Labeling Best Practice in a Challenging Manufacturing Landscape - A survival guide for pharmaceutical companies

whitePaper | November 14, 2022

Rising drug spending and increased desire for expenditure controls are consistent themes across the US, Europe, and emerging markets.

whitePaper | April 1, 2021

Every year, the U.S. pharmaceutical industry develops a variety of new drugs that provide valuable medical benefits. Many of those drugs are expensive and contribute to rising health care costs for the private sector and the federal government. Policymakers have considered policies that would lower drug prices and reduce federal drug expenditures. Such policies would probably reduce the industry’s incentive to develop new drugs.

whitePaper | June 22, 2023

Generic medicines are the backbone of the U.S. prescription drug market, supplying more than 9 out of every 10 prescriptions. And the availability of generic medicines overall is remarkably stable even during challenges such as the COVID-19 pandemic.

whitePaper | June 14, 2022

Multiple sclerosis (MS) is a chronic, inflammatory disease of the central nervous system. Characterized by demyelination and neurodegeneration that affects the communication between the brain and other parts of the body, MS leads to physical and cognitive disability.

whitePaper | March 1, 2023

Shortages of critical medications continue to rise—including drugs used in hospital emergency rooms and to treat cancer, prescription medications, and even common over-the-counter treatments like children’s cold and flu medicine.

whitePaper | March 23, 2023

Sweden is and should remain a leading life sciences nation. The life sciences industry is one of Sweden’s economic base industries with a signifi cant share of our exports.